Phase 3 Systemic Embolism Clinical Trials
2 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–2 of 2 trials
Recruiting
Phase 3
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
Stroke and Systemic Embolism
Bristol-Myers Squibb Australia15,000 enrolled1 locationACTRN12609000026224
Completed
Phase 3
A study comparing the efficacy and safety of once-daily oral rivaroxaban with warfarin for the prevention of stroke and embolism in patients with atrial fibrillation.
StrokeNon-central nervous system systemic embolism in subjects with non-valvular atrial fibrillation.
Bayer Australia Limited14,269 enrolled1 locationACTRN12607000214437